Post Marketing Surveillance Study to Observe Safety and Effectiveness of CRYSVITA® in S. Korean Patients
Latest Information Update: 19 Jan 2024
At a glance
- Drugs Burosumab (Primary)
- Indications Osteomalacia; X-linked dominant hypophosphataemic rickets
- Focus Adverse reactions
- Sponsors Kyowa Kirin Korea
Most Recent Events
- 16 Jan 2024 New trial record